SCHEMBL18263223

SCHEMBL18263223

Oc1cc2ccccc2cc1-c1ccc2ccccc2c1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.60
▸ PTPN22 Q9Y2R2 1/20 0.44
▸ TRPM4 Q8TD43 1/20 0.44
▸ CYP1A2 P05177 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PAK1 Q13153 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ DHFR P00374 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ CYP2A6 P11509 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ NQO2 P16083 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18263183 0.81 POLB (0.59) POLBPTPN22CYP1A2HSD17B10CYP2C9
SCHEMBL19544387 0.79 TRPM4 (0.45) POLBPTPN22TRPM4CYP1A2HSD17B10
SCHEMBL31379796 0.77 TRPM4 (0.52) POLBTRPM4CYP1A2HSD17B10ALDH1A1
SCHEMBL8397149 0.77 TRPM4 (0.52) POLBTRPM4CYP1A2HSD17B10ALDH1A1
SCHEMBL18015440 0.76 POLB (0.52) POLBPTPN22CYP1A2HSD17B10DHFR
SCHEMBL49630 0.76 POLB (1.00) POLBPTPN22CYP1A2HSD17B10USP2
SCHEMBL28875615 0.76 GSTP1 (0.52) POLBCYP1A2HSD17B10CYP2C9CYP2C19
SCHEMBL19544389 0.75 TRPM4 (0.46) POLBTRPM4CYP1A2HSD17B10CYP2C9
SCHEMBL29051366 0.75 POLB (0.50) POLBCYP1A2HSD17B10MAOBALDH1A1
SCHEMBL28031512 0.74 POLB (0.55) POLBPTPN22CYP1A2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11380846-B2 Compound for organic electric element, organic electric element comprising the same and electronic device thereof DUK SAN NEOLUX CO., LTD. (KR) 2022-07-05 — — US disclosed
EP-3305773-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREFOR Duk San Neolux Co., Ltd. (KR) 2018-04-11 — — EP disclosed
US-20180083197-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2018-03-22 — — US disclosed
US-20180083197-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2018-03-22 — — US disclosed
CN-107667098-A Organic electric element compound, organic electric element and its electronic installation using it 德山新勒克斯有限公司 2018-02-06 — — CN disclosed
WO-2016190600-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREFOR 덕산네오룩스 주식회사 2016-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11380846-B2 Compound for organic electric element, organic electric element comprising the same and electronic device thereof PIEZO1, OCIAD1, LEF1 POLB 1775/4885PTPN22 3441/4885TRPM4 93/4885
US-20180083197-A1 COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF PIEZO1, OCIAD1, LEF1 POLB 1775/4885PTPN22 3441/4885TRPM4 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback